VIDEO: Studies in progress generate ‘much to look forward to in sarcoma science’
Click Here to Manage Email Alerts
“There are many exciting studies in progress to look forward to” at future Connective Tissue Oncology Society meetings, according to Candace Haddox, MD.
“This includes large, ongoing studies that may be practice-changing,” Haddox, a sarcoma medical oncologist at Dana-Farber Cancer Institute, told Healio in a video interview.
Haddox discussed randomized, phase 3 trials presented at the 2023 CTOS Annual Meeting, including:
the STRASS2 study of neoadjuvant chemotherapy followed by surgery vs. surgery alone in high-risk retroperitoneal sarcoma;
the Brightline study investigating brigimadlin vs. standard doxorubicin in liposarcoma; and
the prospective INSIGHT study looking at whether tailoring treatment to KIT-resistance mutations impacts treatment response to tyrosine kinase inhibitors (TKIs) in patients with gastrointestinal stromal tumor.
She also discussed an early-phase, trial-in-progress looking at MTA-cooperative PRMT5 inhibitors in tumors with MTAP deletions, as well as the ETCTN trial, which will explore a novel combination of the DNA-PK inhibitor peposertib plus liposomal doxorubicin in select sarcomas with chromosomal instability.
“In summary, much to look forward to in sarcoma science and clinical advancements in the years to come,” Haddox said.
References:
- Bauer S, et al. Paper 61. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.
- Schöffski P, et al. Paper 23. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.
- Van Houdt WJ, et al. Paper 60. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.
- Zhang X, et al. Paper 75. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.
Collapse
Click Here to Manage Email Alerts